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Abstract
A 55-year-old man presented with a large tumor in his lateral ventricles. Magnetic resonance imaging revealed
disseminated lesions in the third and fourth ventricles at the time of diagnosis. The patient underwent a partial
removal of the tumor in the lateral ventricles. Histologically, the surgical specimens showed glioneuronal
differentiation with ganglion or ganglioid cells, Rosenthal fibers, oligodendroglia-like honeycomb appearances, a
spongy pattern, perivascular pseudorosettes, and many hyalinized blood vessels. Papillary structure was not
observed. The neuronal component showed a moderately high labeling index of Ki-67/MIB-1. We diagnosed this
tumor as atypical intraventricular glioneuronal tumor. The disseminated lesions disappeared after chemoradiation
therapy with temozolomide, and the residual tumors in the lateral ventricles remained stable for 3 years after the
surgery. We discuss the pathological diagnosis, therapy and clinical course with review of the literatures.
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Background
Many types of brain tumors originate in the ventricles.
For tumors with neuronal differentiation that occupy
the anterior central part of the lateral ventricles in
adults, central neurocytoma is typically the diagnosis [1].
However, new entities of tumors with neuronal differen-
tiation, which are rare, have been found in this region.
Herein, we report an unusual case of a patient who had
an atypical tumor with glioneuronal differentiation that
arose from the lateral ventricles and that was already
accompanied with intraventricular disseminations at the
time of diagnosis. We discuss the rationale for the
pathological diagnosis on the basis of the immunohisto-
chemistry, the pathophysiology of the dissemination in
the early clinical stages, and possible therapies for this
tumor with a review of the literature.
Case presentation
A 55-year-old man had a 6-month history of memory
loss and stagger. He was admitted to our hospital with
the diagnosis of an intraventricular tumor. Upon admis-
sion, his consciousness level was clear without focal
neurological deficits. His Hasegawa’s dementia scale
(HDR) score had deteriorated to 12/30 points due to his
recent memory disturbance. He did not show any symp-
toms of increased intracranial pressure. His hematologi-
cal tests and physiological function tests were in the
normal range. A computed tomography (CT) scan
showed a large mass lesion of about 6 cm in diameter
in the central part of the lateral ventricles. No calcifica-
tion was shown in the lesion. Magnetic resonance ima-
ging (MRI) revealed that the lesions had spread to the
third and fourth ventricles (Figure 1a-d). MRI did not
show any spinal lesions. The tumor occupying the lat-
eral ventricle showed a low-signal intensity on T1-
weighted images (WI), a high-signal intensity on T2-WI
and fluid-attenuated inversion recovery (FLAIR) images,
and the tumor was enhanced homogeneously with gado-
linium (Gd). Positron emission tomography showed a
homogeneously high uptake of
11C-methionine and a
moderate uptake of
18F-fluorodeoxyglucose. A carotid
angiography showed mild tumor staining. These findings
led us to the primary diagnosis of central neurocytoma.
The patient underwent a subtotal removal of the tumor
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Intraoperatively, the tumor appeared ashy in color. It
was soft superficially and elastic and hard internally.
The tumor was adhered strongly to the septum pelluci-
dum and moderately to the walls of the anterior horns
and the bodies of the lateral ventricles. The choroidal
arteries fed the tumor. Incidentally, the body of the
right fornix was injured in order to remove the tumor
extending into the third ventricle. Postoperative MRI
showed that the tumor remained in the tip of the left
anterior horn and the fourth ventricle. After the opera-
tion, the patient’s memory disturbance worsened, and
his postoperative HDS-R scale was 10/30.
Pathological examination
Formalin-fixed, paraffin-embedded tissue sections were
examined with hematoxylin-eosin (HE) staining and
immunohistochemistry. The primary antibodies and
their dilution with buffer were as follows: rabbit polyclo-
nal anti-olig2 antibody (1:200; Millipore, Temecula, CA),
polyclonal anti-vimentin antibody (1:200; Dako,
Glostrup, Denmark), mouse monoclonal anti-glial fibril-
lary acidic protein (GFAP) antibody (1:500; Dako),
mouse monoclonal anti-synaptophysin (Syn) antibody
(1:50; Millipore), mouse monoclonal anti-tubulin, bIII
isoform (TuJ1) antibody (1:200; Millipore), monoclonal
anti-neuronal nuclear antigen (Neu-N) antibody (1:100;
Millipore), monoclonal anti-microtubule associated pro-
tein-2 (MAP-2) antibody (1:100; Millipore), monoclonal
anti-neuron-specific enolase (NSE) and monoclonal
anti-Ki-67/MIB-1 antibody (1:50; Dako). Antigen retrie-
val using an autoclave (121°C, 15 min) was performed
for all antibodies. An Envision kit (Dako) was used as a
source of secondary antibodies conjugated to dextran
polymer and hydrogen peroxidase, and 3,3-diaminoben-
zidine was used as the chromogen.
Pathological findings
HE slides exhibited a variety of glioneuronal tumors.
Some ganglions or ganglioid cells were observed with a
background of neuropil (Figure 2a). Spongy patterns
with many bipolar cells were also observed (Figure 2b).
Oligodendroglioma-like honeycomb appearances were
seen in part of the tumor (Figure 2c). Part of the tumor
included a cluster of minigemistocytes (Figure 2d).
Many hyalinized blood vessels were very visible, and a
small amount of neoplastic blood vessels and endothelial
proliferation was observed (Figure 2e). These findings
exhibited some resemblance to pilocytic astrocytomas
(PA), except for the presence of the ganglion cells. In
some areas, cells with small round nuclei that sur-
rounded and enclosed the vessels mimicked perivascular
pseudorosettes (Figure 2f). Mitotic figures and necrotic
areas were observed infrequently.
The results of the immunohistochemistry are shown in
Table 1. The specimens exhibited both glial components
and neuronal components. The glial components were
strongly positive for GFAP and vimentin. In addition, the
minigemistocytes and the Rosenthal fibers were strongly
positive for GFAP. Syn- or MAP-2-positive cells were not
observed. The neuronal components included cells that
had moderately uniform oval nuclei. These cells were nega-
tive for GFAP and vimentin. Only the endothelial cells and
reactive astrocytes were positive for GFAP and vimentin.
The cells with oval nuclei were strongly positive for NSE,
MAP-2, Syn, NeuN, Olig2, and they were mildly positive
for TuJ1 (Figure 3a-f). The cells near the perivascular pseu-
dorosettes were strongly positive for NSE and MAP-2 (Fig-
ure 3g, h). Some scattered cells were positive for TuJ1 and
Olig2 around the perivascular pseudorosettes. MIB-1 label-
ing indices were 0.8% in the glial component and 8% in the
neuronal component. These pathological findings resulted
in the diagnosis of an intraventricular tumor with atypical
glioneuronal differentiation.
Postoperative course
For the residual tumor, the patient underwent intensity-
modulated radiation therapy (IMRT) using helical
Figure 1 Magnetic resonance imaging (MRI) on admission.M R I
[a: T1 plain-weighted image, b-d: Gadolinium-
diethylenetriaminepentaacetic acid (Gd-DTPA)-enhanced images]
scans showed a mass lesion in the lateral ventricles, the third
ventricle, and the fourth ventricle. The mass lesion was enhanced
with Gd-DTPA.
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ian dose of 30.6 Gy. Temozolomide (TMZ: 150 mg/m
2)
was orally administered as a concomitant and adjuvant
therapy following radiation therapy. Twelve months after
the surgery, MRI with Gd revealed that the disseminated
lesions in the lateral ventricles and fourth ventricle had
disappeared. A small residual nodule remained in the tip
o ft h el e f ta n t e r i o rh o r n .M R Iw i t hG ds h o w e dt h a tt h e
residuum had remained stable for 30 months after the
surgery. His memory disturbance gradually subsided, and
his HDS-R scale improved to 25/30.
Discussion
The tumor in this case exhibited components that
showed perinuclear halos, which were suggestive of
central neurocytoma. However, the tumor differed
from central neurocytoma because it exhibited a small
number of ganglion cells or ganglioid cells that were
immunohistochemically positive for multiple neuronal
markers. Additionally, the glial components observed
in this tumor are uncommon in central neurocytomas.
Although there is a possibility that these glial compo-
nents might be trapped cell in the tumor, we regarded
them as neoplastic cells because these components in
Figure 2 Photomicrographs of hematoxylin-eosin staining. (a) Several ganglioid cells with moderately abundant cytoplasm were observed.
(b) A spongy pattern, (c) an oligodendroglial honeycomb pattern, (d) distinctive minigemistocytes, (e) well-developed hyalinized blood vessels,
and (f) perivascular pseudorosette pattern. (a: ×400; b, e, f: ×100; c, d: ×200).
Table 1 Results of the immunohistochemistry
Glial components Neuronal components
GFAP ++ +/-
Vimentin ++ +/-
NSE + ++
MAP-2 - ++
NeuN +/- ++
TuJ1 + +
Olig2 - ++
Syn - ++
Mib-1 LI 0.8% 8%
GFAP: glial fibrillary astrocytic protein, NSE: neuron-specific enolase, MAP-2:
microtubule-associated protein 2, NeuN: neuronal nuclear antigen, TuJ1: anti-
tubulin, bIII isoform, Syn: synaptophysin, LI: labeling index, -: negative, +/-:
slight, +: mild, ++: strong.
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the contrary, neuronal differentiation was not suffi-
cient for central neurocytoma. Furthermore, the
spongy pattern and abundant hyalinized vessels
observed in this tumor were not consistent with the
histological features of central neurocytoma.
Hyalinized vessels are more frequently observed in
papillary glioneuronal tumors (PGNT). However, the
tumor of this case had less papillary structures and
less ganglion cells than PGNTs, in which tumor cells
are typically arranged around vessels, forming pseudo-
papillary structures [2].
Figure 3 Photomicrographs showing immunohistochemistry for neuronal markers. (a) neuron-specific enolase (NSE), (b) microtubule-
associated protein-2 (MAP-2), (c) Synaptophysin, (d) neuronal nuclear antigen (NeuN), (e) tubulin, bIII isoform (TuJ1). The markers in a-d were
diffusely positive in the part of the tumor with neuronal differentiation. However, TuJ1 was only weakly positive there. Olig2-positive cells were
also observed in the same area (f). The cells comprising the perivascular pseudorosette were strongly positive for NSE (g) and MAP-2 (h), a-f:
×100; g and h: ×200.
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and honeycomb-like components have often been asso-
ciated with PA [3]. However, PA is usually found in
younger people. Additionally, the lateral ventricle is not
a typical site for PA, which usually derives from the
optic chiasm, hypothalamus, thalamus, basal ganglia,
cerebral hemispheres, or cerebellar hemispheres [4].
Along with PGNTs, rosette-forming glioneuronal
tumors of the fourth ventricle (RGNT) were recently
listed in the fourth edition of the World Health Organi-
zation Classification of Tumours of the Central Nervous
System [4,5]. It is notewothy that RGNTs have been
reported to partly include similar features to PA, such
as Rosenthal fibers, oligodendroglial components, and
hyalinized vessels [6]. The tumor of the present case
may have been more similar to a RGNT rather than a
PGNT because it exhibited PA-like features, a small
amount of ganglion cells, and perivascular pseudoro-
settes that are unlikely in PGNTs [2]. The average age
of onset in RGNT is reported to be higher than that in
PGNT [4,6]. The present patient had another lesion in
the fourth ventricle. However, we suggest that the lesion
was a dissemination from the tumor of the lateral ven-
tricle because of the tumor size and because of the
patient’s initial clinical symptoms. Thus, the fourth ven-
tricle was not the primary site of the tumor in this case,
which differs from RGNT cases.
The moderately high Ki-67 labeling index (LI) was
another clue for the diagnosis of this tumor. The Ki-67
LI of ordinary glioneuronal tumors or central neurocy-
toma is less than 3%. The differential diagnoses were
atypical central neurocytoma and PA with atypical fea-
tures. Considering these histological variabilities of neu-
ronal and glial component and the atypical histological
findings, we finally diagnosed this case as an intraventri-
cular tumor with atypical glioneuronal differentiation.
A c c o r d i n gt oI s h i z a w ae ta l .[ 7 ] ,t h e r ew a sac a s eo f
PGNT with proliferation of minigemistocytic compo-
nent, which showed a high Ki-67 LI. This findings were
considered to coincide with our case. However, it was
reported that high Ki-67 LI in a case of PGNT was not
nessesary associated with poor prognosis [8].
To the best of our knowledge, 11 cases of intracranial
glioneuronal tumors (1 cases of PGNTs [9], 9 of malig-
nant glioneuronal tumors [10] and 1 of RGNT [11]) pre-
senting dissemination in the clinical course have been
reported. There are also 3 cases of spinal cord glioneur-
onal tumors with neuropil-like islands presenting
meningeal dissemination [12-14]. Javahery et al. [9]
reported on a case of a 13-year-old girl with PGNT. She
had a primary cystic lesion in the left frontal lobe,
which was totally removed. However, 43 months after
the initial surgery, the tumor relapsed adjacent to the
primary site with dissemination to the pulvinar nucleus
and the medial left thalamus, which disappeared with
radiation therapy and concomitant temozolomide ther-
apy. Varlet et al. [10] reported a summary of 9 cases
with malignant glioneuronal tumors that exhibited disse-
mination with a median time to the event of 19 months
after the initial treatment. Wang et al. [11] reported a
case of 16-year-old girl with RGNT initially presenting
intraventricular dissemination. She underwent a neu-
roendoscopic biopsy and postoperative radiotherapy.
Accordingly, there were only 2 cases of intracranial glio-
neuronal tumors presenting with intraventricular disse-
mination at such an early time including our case.
Attention may need to be paid to the dissemination in
the case with glioneuronal tumor including the case of
spinal cord origin.
Varlet et al. [10] reported that gross total resection of
a malignant glioneuronal tumor was an independent
and statistically significant prognostic factor. Addition-
ally, they also stated that focal or craniospinal radiation
therapy seemed neither to control local tumor growth
nor to prevent dissemination of these tumors. Although
our case underwent a partial resection of the tumor, the
subsequent IMRT and adjuvant chemotherapy with
temozolomide greatly reduced the residual tumors in
the fourth ventricle and the anterior horn of the lateral
ventricle. MRI with Gd demonstrated no recurrence of
the residual small tumor 30 months after the surgery.
Following surgery, radiation therapy with concomitant
administration of TMZ has recently become the stan-
dard therapy for malignant gliomas. As shown by the
cases of Javahery et al. [9] and the present case, this
therapy may also be effective for glioneuronal tumors.
Conclusion
This is the rare case of glioneuronal tumor to present
intraventricular dissemination at diagnosis, which have a
possibility of transitional form between glial and neuro-
nal components. The case was successfully treated wih a
possible reductive surgery followed by IMRT with
administarion of TMZ.
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